Free Trial
NASDAQ:RPID

Rapid Micro Biosystems Q2 2025 Earnings Report

Rapid Micro Biosystems logo
$3.49 -0.14 (-3.86%)
As of 04:00 PM Eastern

Rapid Micro Biosystems EPS Results

Actual EPS
N/A
Consensus EPS
-$0.26
Beat/Miss
N/A
One Year Ago EPS
N/A

Rapid Micro Biosystems Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rapid Micro Biosystems Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 1, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Rapid Micro Biosystems Earnings Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Rapid Micro Biosystems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rapid Micro Biosystems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapid Micro Biosystems and other key companies, straight to your email.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ:RPID) (NASDAQ: RPID) develops and commercializes rapid microbial detection and identification systems for quality control laboratories in the pharmaceutical, biotechnology, medical device and consumer health industries. Founded in 2001 and headquartered in Woburn, Massachusetts, the company offers automated platforms that enable manufacturers to detect microbial contamination more quickly than traditional culture-based methods, helping to accelerate product release and improve patient safety.

The company’s flagship RAPID™ instruments combine proprietary fluorescent staining, high‐resolution imaging and advanced software analytics to provide quantitative and qualitative microbial testing results in hours rather than days. Rapid Micro’s product suite includes consumables, reagents and accessories designed to streamline sample preparation and support compliance with global regulatory standards such as FDA 21 CFR Part 11 and EU Annex 1.

In addition to its core instrumentation and consumable offerings, Rapid Micro Biosystems provides installation, validation, training and ongoing technical support to ensure seamless integration into existing quality control workflows. The company’s dedicated field service and applications teams work closely with clients to qualify methods, optimize protocols and maintain compliance across multiple geographies.

Rapid Micro Biosystems went public in 2020 and is listed on the NASDAQ under the symbol RPID. The company serves a global customer base spanning North America, Europe and the Asia-Pacific region. Led by a seasoned management team with deep expertise in microbiology, engineering and regulatory affairs, Rapid Micro is positioned as a strategic partner in the digital transformation of pharmaceutical and life sciences manufacturing.

View Rapid Micro Biosystems Profile

More Earnings Resources from MarketBeat